Difference between revisions of "Oligoastrocytoma"
Jump to navigation
Jump to search
Jensflorian (talk | contribs) m (→IHC: wikify) |
Jensflorian (talk | contribs) (WHO 2016) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Oligoastrocytoma''' is an uncommon [[neuropathology tumour]] that is | '''Oligoastrocytoma, NOS''' is an uncommon [[neuropathology tumour]] that is '''no longer''' a distinct entity.<ref name=pmid25143301>{{Cite journal | last1 = Sahm | first1 = F. | last2 = Reuss | first2 = D. | last3 = Koelsche | first3 = C. | last4 = Capper | first4 = D. | last5 = Schittenhelm | first5 = J. | last6 = Heim | first6 = S. | last7 = Jones | first7 = DT. | last8 = Pfister | first8 = SM. | last9 = Herold-Mende | first9 = C. | title = Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. | journal = Acta Neuropathol | volume = 128 | issue = 4 | pages = 551-9 | month = Oct | year = 2014 | doi = 10.1007/s00401-014-1326-7 | PMID = 25143301 }}</ref> | ||
==General== | ==General== | ||
*Mixed tumour by definition. | *Mixed tumour by definition. | ||
* | *After [[IDH-1]]/2 mutation screening and LOH 1p/19q analysis almost all tumors are either classified as ''oligodendroglioma'' or ''astrocytoma''.<ref name=pmid25143301/> | ||
*The NOS category is reserved for cases without genetic testing.<ref>{{Cite journal | last1 = Louis | first1 = DN. | last2 = Perry | first2 = A. | last3 = Reifenberger | first3 = G. | last4 = von Deimling | first4 = A. | last5 = Figarella-Branger | first5 = D. | last6 = Cavenee | first6 = WK. | last7 = Ohgaki | first7 = H. | last8 = Wiestler | first8 = OD. | last9 = Kleihues | first9 = P. | title = The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. | journal = Acta Neuropathol | volume = 131 | issue = 6 | pages = 803-20 | month = Jun | year = 2016 | doi = 10.1007/s00401-016-1545-1 | PMID = 27157931 }}</ref> | |||
Two types exist: | |||
*Oligoastrocytoma, NOS (Grade II WHO; ICD-O: 9382/3) | |||
*Anaplastic Oligoastrocytoma, NOS (Grade III WHO; ICD-O: 9382/3) | |||
==Microscopic== | ==Microscopic== | ||
| Line 14: | Line 20: | ||
*[[Anaplastic astrocytoma]]. | *[[Anaplastic astrocytoma]]. | ||
*[[Oligodendroglioma]]. | *[[Oligodendroglioma]]. | ||
*[[Diffuse astrocytoma]]. | |||
*[[Anaplastic oligodendroglioma]] | |||
*[[Glioblastoma]] | |||
===IHC=== | ===IHC=== | ||
*Oligodendroglioma-like cells: MAP2 +ve (cytoplasm). | *Oligodendroglioma-like cells: [[MAP2]] +ve (cytoplasm). | ||
*Astrocytoma-like cells: GFAP +ve (cytoplasm, nuclear membrane). | *Astrocytoma-like cells: GFAP +ve (cytoplasm, nuclear membrane). | ||
Others: | Others: | ||
*Ki-67 | *Ki-67 3-10%. | ||
* | *ATRX loss (in cases without LOH1p/19q). | ||
*[[IDH-1]] +ve. (85%) | *[[IDH-1]] +ve. (85%). | ||
==See also== | ==See also== | ||
| Line 31: | Line 40: | ||
[[Category:Neuropathology tumours]] | [[Category:Neuropathology tumours]] | ||
[[Category:WHO grade II tumours]] | |||
Latest revision as of 10:38, 20 May 2016
Oligoastrocytoma, NOS is an uncommon neuropathology tumour that is no longer a distinct entity.[1]
General
- Mixed tumour by definition.
- After IDH-1/2 mutation screening and LOH 1p/19q analysis almost all tumors are either classified as oligodendroglioma or astrocytoma.[1]
- The NOS category is reserved for cases without genetic testing.[2]
Two types exist:
- Oligoastrocytoma, NOS (Grade II WHO; ICD-O: 9382/3)
- Anaplastic Oligoastrocytoma, NOS (Grade III WHO; ICD-O: 9382/3)
Microscopic
Features:
- Astrocytoma-like and oligodendroglioma-like:
- Oligodendroglioma-like cells = round nucleus, peri-nuclear clearing.
- Astrocytoma-like cells = non-ovoid/elongated nucleus.
DDx:
- Anaplastic astrocytoma.
- Oligodendroglioma.
- Diffuse astrocytoma.
- Anaplastic oligodendroglioma
- Glioblastoma
IHC
- Oligodendroglioma-like cells: MAP2 +ve (cytoplasm).
- Astrocytoma-like cells: GFAP +ve (cytoplasm, nuclear membrane).
Others:
- Ki-67 3-10%.
- ATRX loss (in cases without LOH1p/19q).
- IDH-1 +ve. (85%).
See also
References
- ↑ 1.0 1.1 Sahm, F.; Reuss, D.; Koelsche, C.; Capper, D.; Schittenhelm, J.; Heim, S.; Jones, DT.; Pfister, SM. et al. (Oct 2014). "Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.". Acta Neuropathol 128 (4): 551-9. doi:10.1007/s00401-014-1326-7. PMID 25143301.
- ↑ Louis, DN.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, WK.; Ohgaki, H.; Wiestler, OD. et al. (Jun 2016). "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.". Acta Neuropathol 131 (6): 803-20. doi:10.1007/s00401-016-1545-1. PMID 27157931.